{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:20:02Z","timestamp":1787142002701,"version":"build-2736575974"},"reference-count":95,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Medications for opioid use disorder (MOUD), such as methadone and buprenorphine, are effective strategies for treatment of opioid use disorder (OUD) and reducing overdose risk. MOUD treatment rates continue to be low across the US, and currently, some evidence suggests access to evidence-based treatment is becoming increasingly difficult for those with OUD as a result of the 2019 novel corona virus (COVID-19). A major underutilized source to address these serious challenges in the US is community pharmacy given the specialized training of pharmacists, high levels of consumer trust, and general availability for accessing these service settings. Canadian, Australian, and European pharmacists have made important contributions to the treatment and care of those with OUD over the past decades. Unfortunately, US pharmacists are not permitted to prescribe MOUD and are only currently allowed to dispense methadone for the treatment of pain, not OUD. US policymakers, regulators, and practitioners must work to facilitate this advancement of community pharmacy-based through research, education, practice, and industry. Advancing community pharmacy-based MOUD for leading clinical management of OUD and dispensation of treatment medications will afford the US a critical innovation for addressing the opioid epidemic, fallout from COVID-19, and getting individuals the care they need.<\/jats:p>","DOI":"10.1080\/08897077.2020.1787300","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T11:55:59Z","timestamp":1595418959000},"page":"269-274","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":46,"title":["Medication Treatment for Opioid use Disorder and Community Pharmacy: Expanding Care during a National Epidemic and Global Pandemic"],"prefix":"10.1177","volume":"41","author":[{"given":"Gerald","family":"Cochran","sequence":"first","affiliation":[{"name":"Greater Intermountain Node, a NIH NIDA Clinical Trial Network node and Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), University of Utah School of Medicine, Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bruneau","sequence":"additional","affiliation":[{"name":"Department of family medicine and emergency medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Cox","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-8871","authenticated-orcid":false,"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Greater Intermountain Node, a NIH NIDA Clinical Trial Network node and Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), University of Utah School of Medicine, Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA;"},{"name":"Vulnerable Veteran Innovative PACT (VIP) Initiative; Informatics, Decision-Enhancement, and Analytic Sciences Center (IDEAS Center), VA Salt Lake City Health Care System, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"e_1_3_1_2_2","volume-title":"Key Substance Use and Mental Health Indicators in the United States: results from the 2018 National Survey on Drug Use and Health","author":"SAMHSA","year":"2019","unstructured":"SAMHSA. Key Substance Use and Mental Health Indicators in the United States: results from the 2018 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2019."},{"key":"e_1_3_1_3_2","unstructured":"Centers for Disease Control and Prevention. U.S. opioid prescribing rate maps. https:\/\/www.cdc.gov\/drugoverdose\/maps\/rxrate-maps.html. Published 2018. Accessed November 24 2018."},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.1673"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2016.1141"},{"issue":"13","key":"e_1_3_1_6_2","first-page":"S243","article-title":"The economic burden of the opioid epidemic on states: the case of Medicaid","volume":"25","author":"Leslie DL","year":"2019","unstructured":"Leslie DL, , Ba DM, , Agbese E, , Xing X, , Liu G. The economic burden of the opioid epidemic on states: the case of Medicaid. Am J Manag Care. 2019;25(13 Suppl):S243\u2013S249.","journal-title":"Am J Manag Care"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2018.05049"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.06.008"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.05.003"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000676"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.05.039"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"e_1_3_1_13_2","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick RP","year":"2014","unstructured":"Mattick RP, , Breen C, , Kimber J, , Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1402780"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1706626"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300256"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.11.003"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.10.014"},{"key":"e_1_3_1_19_2","first-page":"CD004145","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection","volume":"8","author":"Gowing L","year":"2011","unstructured":"Gowing L, , Farrell MF, , Bornemann R, , Sullivan LE, , Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8):CD004145.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2005.52"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00352.x"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/00952990701523698"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.3109\/10826080902873010"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.10.015"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.14436"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302664"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1752351"},{"key":"e_1_3_1_29_2","unstructured":"Priest K. The COVID-19 Pandemic: practice and policy considerations for patients with opioid use disorder. Health Affairs Blog. 2020."},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1212"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1210"},{"key":"e_1_3_1_32_2","unstructured":"NIDA. COVID-19: Potential implications for individuals with substance use disorders. https:\/\/www.drugabuse.gov\/about-nida\/noras-blog\/2020\/04\/covid-19-potential-implications-individuals-substance-use-disorders. Published 2020. Accessed April 6."},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1141"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02247.x"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/10826081003682917"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2016.1277816"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2016.1188952"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2019.305193"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-020-00370-7"},{"key":"e_1_3_1_40_2","article-title":"A primary care response to COVID-19 for patients with an opioid use disorder","author":"Wilson CG","year":"2020","unstructured":"Wilson CG, , Ramage M, , Fagan EB. A primary care response to COVID-19 for patients with an opioid use disorder. J Rural Health. 2020. doi:10.1111\/jrh.12438.","journal-title":"J Rural Health"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2016.1267225"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2015.1023455"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-014-9904-5"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-014-9866-7"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/1940-0640-9-3"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183172"},{"key":"e_1_3_1_47_2","volume-title":"Pharmacists\u2019 Impact on Patient Safety","author":"American Pharmacists Association","unstructured":"American Pharmacists Association. n.d. Pharmacists\u2019 Impact on Patient Safety. Washington DC: American Pharmacists Association."},{"key":"e_1_3_1_48_2","unstructured":"Riffkin R. Americans rate nurses highest on honesty ethical standards. Gallup. http:\/\/www.webcitation.org\/6hZbvKPDQ. Published 2014. Accessed May 17 2016."},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9845-1"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000148"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107570"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2017.01.017"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.2307\/3343343"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.4066\/AMJ.2011.706"},{"key":"e_1_3_1_55_2","unstructured":"Samet JH Botticelli M. It's time for methadone to be prescribed as part of primary care. https:\/\/www.statnews.com\/2018\/07\/05\/methadone-prescribed-primary-care\/. Published 2018. Accessed April 30 2020."},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-018-4801-3"},{"key":"e_1_3_1_57_2","unstructured":"Methadone Maintenance Treatment Program Standards and Clinical Guidelines [press release]. Toronto: College of Physicians and Surgeons of Ontario; 2011."},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1211\/ijpp.15.3.0005"},{"key":"e_1_3_1_59_2","volume-title":"Supervised Self Administration of Methadone and Buprenorphine Guidelines for Pharmacists and Pharmacy Technicians","author":"NHS","year":"2010","unstructured":"NHS. Supervised Self Administration of Methadone and Buprenorphine Guidelines for Pharmacists and Pharmacy Technicians. Cumbria: National Health Service; 2010."},{"issue":"515","key":"e_1_3_1_60_2","first-page":"444","article-title":"The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales","volume":"55","author":"Strang J","year":"2005","unstructured":"Strang J, , Sheridan J, , Hunt C, , Kerr B, , Gerada C, , Pringle M. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. Br J Gen Pract. 2005;55(515):444\u2013451.","journal-title":"Br J Gen Pract"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-019-0158-0"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-016-0055-4"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30337-7"},{"key":"e_1_3_1_64_2","volume-title":"National Opioid Pharmacotherapy Statistics Annual Data Collection 2019","author":"Austrailian Institute of Health and Welfare.","year":"2020","unstructured":"Austrailian Institute of Health and Welfare. National Opioid Pharmacotherapy Statistics Annual Data Collection 2019. Sydney, Australia: Austrailian Institute of Health and Welfare; 2020."},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-018-0402-3"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1735"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000156"},{"key":"e_1_3_1_68_2","unstructured":"Insinger A. Methadone clinic lines and packed waiting rooms leave clients vulnerable to the coronavirus. In: STAT News; 2020. Boston."},{"key":"e_1_3_1_69_2","unstructured":"Levander X Wakeman S. Covid-19 will worsen the opioid overdose crisis if we don't prepare now. In: STAT News; 2020. Boston."},{"key":"e_1_3_1_70_2","unstructured":"Grierson J. Methadone to be supplied without new prescription during Covid-19 crisis. The Guardian. April 8 2020."},{"key":"e_1_3_1_71_2","unstructured":"Clun R. Opioid addiction treatment must change during pandemic experts say. The Sydney Morning Herald. April 24 2020."},{"key":"e_1_3_1_72_2","unstructured":"Tait C Gee M Woo A. Pandemic restrictions reshape opioid treatment as doctors sound alarm. The Globe and Mail: Alberta. 2020."},{"key":"e_1_3_1_73_2","unstructured":"Controlled Drugs and Substances Act (CDSA) Subsection 56(1); Class exemption for patients practitioners and pharmacists prescribing and providing controlled substances in Canada during the coronavirus pandemic \u00a75; Subsection 56(1) 2020."},{"key":"e_1_3_1_74_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2018.1452327"},{"key":"e_1_3_1_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-011-0222-2"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa060"},{"key":"e_1_3_1_77_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1616349"},{"key":"e_1_3_1_78_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2019.1670210"},{"key":"e_1_3_1_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-019-00790-x"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186315"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.11.006"},{"key":"e_1_3_1_82_2","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2013059"},{"key":"e_1_3_1_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2013.02.004"},{"key":"e_1_3_1_84_2","volume-title":"Guidance for Clinical Investigators, Sponsors, and Irbs Investigational New Drug Applications (Inds) \u2014 Determining Whether Human Research Studies Can Be Conducted Without an IND","author":"FDA","year":"2015","unstructured":"FDA. Guidance for Clinical Investigators, Sponsors, and Irbs Investigational New Drug Applications (Inds) \u2014 Determining Whether Human Research Studies Can Be Conducted Without an IND. Rockville, MD: Center for Drug Evaluation and Research, Food and Drug Administration; 2015."},{"key":"e_1_3_1_85_2","doi-asserted-by":"publisher","DOI":"10.1177\/1559827617691721"},{"key":"e_1_3_1_86_2","doi-asserted-by":"publisher","DOI":"10.2147\/IPRP.S63822"},{"key":"e_1_3_1_87_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-015-0058-x"},{"key":"e_1_3_1_88_2","volume-title":"Collaborative Practice Agreements and Pharmacists\u2019 Patient Care Services: A Resource for Pharmacists","author":"CDC","year":"2013","unstructured":"CDC. Collaborative Practice Agreements and Pharmacists\u2019 Patient Care Services: A Resource for Pharmacists. Atlanta, GA: US Dept. of Health and Human Services, Centers for Disease Control and Prevention; 2013."},{"key":"e_1_3_1_89_2","doi-asserted-by":"publisher","DOI":"10.5688\/aj7410S11"},{"key":"e_1_3_1_90_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-1-3"},{"key":"e_1_3_1_91_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1694618"},{"key":"e_1_3_1_92_2","unstructured":"Medscape. State CE Requirements for Pharmacists. https:\/\/www.medscape.org\/public\/pharmcestaterequirements. Published 2018. Accessed April 27 2020."},{"key":"e_1_3_1_93_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7030106"},{"key":"e_1_3_1_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.01.004"},{"key":"e_1_3_1_95_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2148"},{"key":"e_1_3_1_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ptdy.2018.02.038"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2020.1787300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2020.1787300","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2020.1787300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:07:47Z","timestamp":1780492067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2020.1787300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1080\/08897077.2020.1787300"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2020.1787300","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}